University of Pennsylvania Health System

Kyiv to Host International Healthcare Summit on War Zone Medicine

Retrieved on: 
Tuesday, October 31, 2023
Public health, Clinical professor, Surgeon General of the United States, California Pacific Medical Center, Organization, Summit, Amputation, University of Maryland School of Public Health, Learning, Non-governmental organization, Surgeon, International healthcare accreditation, Hospital, Stanford University School of Medicine, Maryland School, University, Pain management, University of Pennsylvania Health System, Mayo Clinic, Rear admiral, Saint Louis University School of Medicine, Dentistry, Pharmaceutical industry

COLUMBUS, Ohio, Oct. 31, 2023 /PRNewswire/ -- (JANZ Corporation) -- As war rages in Ukraine and Gaza, a former U.S. Surgeon General will be among the medical professionals gathering in Kyiv next week to discuss the challenges of providing medical care in active war zones.

Key Points: 
  • Surgeon General will be among the medical professionals gathering in Kyiv next week to discuss the challenges of providing medical care in active war zones.
  • To learn more and/or register to attend physically or virtually for the International Healthcare Summit-Ukraine 2023, please visit www.internationalhealthcaresummit.org .
  • "The situation in Ukraine is absolutely catastrophic," said Dr. Andrii Strokan, chief clinical medical officer at Feofaniya Hospital in Kyiv, Ukraine.
  • Strokan, who led the team of surgeons visiting the Mayo Clinic, will be joined in Kyiv at the healthcare summit by former Surgeon General of the United States (Acting), Rear Admiral
    (ret.)

Flatiron Health Launches New Strategic Collaboration to Advance Health Insights and Equity of Cancer Care

Retrieved on: 
Monday, October 23, 2023
Other Health, Research, Managed Care, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Biotechnology, FDA, Health, Flatiron, Perelman School of Medicine at the University of Pennsylvania, MD, University, Organization, Evidence-based medicine, Health equity, Cancer, HC, NCCN, EHR, Patient, University of Pennsylvania Health System, GM, ACC, Pharmaceutical industry, Medical imaging, Medicine

Access to evidence-based treatment recommendations will promote high levels of guideline-concordant care, while improving health equity and patient experiences and reducing unnecessary spending.

Key Points: 
  • Access to evidence-based treatment recommendations will promote high levels of guideline-concordant care, while improving health equity and patient experiences and reducing unnecessary spending.
  • The two organizations will also work together to optimize the usability and functionality of Flatiron Assist™.
  • Flatiron Assist™ is an oncology-specific clinical decision support platform that prioritizes the latest evidence-based medicine, site-preferred pathways and clinical research at the point of care.
  • “As cancer care options increase in complexity, this tool will help provide high-quality, guideline-concordant care, maximizing benefits for our patients.”

AVS to Present PULSE™ IVL Clinical Trial Data at 2023 TCT Conference

Retrieved on: 
Wednesday, October 18, 2023
Health, Medical Devices, General Health, Clinical Trials, Research, Science, Cardiology, Practitioner, Peripheral vascular examination, Radiology, PULSE, CRF, Moscone Center, MD, Conference, Artery, IVL, Surgeon, POWER, Pennsylvania Hospital, University, Safety, TCT, University of Pennsylvania Health System, Pain, Patient, Pharmaceutical industry, Medical imaging, AVS

Jon George, MD, a medical advisor to AVS and interventional cardiologist at Pennsylvania Hospital, University of Pennsylvania Health System, will present the abstract during the Peripheral Vascular Intervention Techniques session on Wednesday, Oct. 25, 2023.

Key Points: 
  • Jon George, MD, a medical advisor to AVS and interventional cardiologist at Pennsylvania Hospital, University of Pennsylvania Health System, will present the abstract during the Peripheral Vascular Intervention Techniques session on Wednesday, Oct. 25, 2023.
  • “The POWER PAD I clinical trial results represent groundbreaking data for the future of pulse intravascular lithotripsy,” said Robert Chisena, Ph.D., Chief Technology Officer at AVS.
  • “We are honored to present these new findings at the TCT Conference, the world’s premier conference for cardiovascular data unveiling.”
    The TCT conference has served as a premier showcase of cutting-edge educational content in interventional cardiovascular medicine for over three decades.
  • To learn more about AVS and the PULSE IVL™ System, please visit https://www.avspulse.com .

HealthShare Exchange Announces Grant to Connect PA Residents with Social Services

Retrieved on: 
Tuesday, October 17, 2023
Technology, Nursing, Hospitals, Professional Services, Software, Social Services, Managed Care, Health, Data Management, HealthShare Exchange, Hospital, Andrew Kohut, Commonwealth, Medicaid, CHIP, Accountable care organization, Department of Human Services, Transport, HSX, EMR, PA, Medicare, HIE, SDOH, University of Pennsylvania Health System, Serving His Children, Acos, Patient, Housing, Health insurance

This platform—which will be known as PA Navigate—will help screen residents for needs that impact their ability to thrive, such as childcare, transportation, nutritional support, housing insecurity and many other social determinants of health (SDOH).

Key Points: 
  • This platform—which will be known as PA Navigate—will help screen residents for needs that impact their ability to thrive, such as childcare, transportation, nutritional support, housing insecurity and many other social determinants of health (SDOH).
  • Once needs are identified, residents may be referred to Community Based Organizations (CBOs) that can provide needed services, and CBOs will be able to “close the loop” with the person making referrals so they know the resident received services.
  • “We are committed to supporting our community, our members and especially those individuals in need of these services.
  • HSX’s grant has listed more than 50 regional healthcare providers, payers and CBOs as seeking to integrate with the statewide system.

Cimeio Therapeutics Announces Research Collaboration With the University of Pennsylvania to Conduct Preclinical Studies of a CD45 Universal CAR T Cell Therapy for Patients With Blood and Bone Marrow Cancers

Retrieved on: 
Monday, October 16, 2023
Research, General Health, Pharmaceutical, Oncology, Infectious Diseases, University, Education, Clinical Trials, Science, Biotechnology, Stem Cells, Health, CD45, Drug development, Medical laboratory, Pathology, Nephrology, Penn, Multiple myeloma, Medicine, HSC, Lymphoma, Blood, Patient, Therapy, Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania Health System, CAR, Bone marrow, Leukemia, Biozentrum University of Basel, Pharmaceutical industry, Vaccine, Immunotherapy

The Penn team will combine Cimeio Therapeutics’ proprietary epitope-editing and CD45-targeting technologies with Penn Medicine’s epitope-editing and CAR T cell technology to create a CD45-targeting CAR T cell therapy and paired epitope-edited hematopoietic stem cell (HSC).

Key Points: 
  • The Penn team will combine Cimeio Therapeutics’ proprietary epitope-editing and CD45-targeting technologies with Penn Medicine’s epitope-editing and CAR T cell technology to create a CD45-targeting CAR T cell therapy and paired epitope-edited hematopoietic stem cell (HSC).
  • Given that CD45 is highly expressed on nearly all blood cells, this therapy could be a universal CAR T cell therapy for blood cancers.
  • Recent findings have demonstrated the ability to epitope edit CD45, which is a receptor broadly expressed on the surface of healthy HSCs as well as many blood and bone marrow cancers.
  • The company plans to develop that therapy with CD45 epitope shielded cells for blood cancers and autoimmune diseases among other indications.

More Aggressive Treatment Doesn't Impact Quality of Life for Metastatic Colorectal Cancer Patients, According to New Study in JNCCN

Retrieved on: 
Thursday, October 12, 2023
Neoplasm, Quality of life, CAPOX, Max Healthcare, Penn Medicine Princeton Medical Center, Bevacizumab, Risk, Radiation, EORTC, SAE, Șaeș, Survival, Outline of health sciences, University, Disease, FOLFOX, Patient, Quality of life (healthcare), FACP, University of Pennsylvania Health System, Fatigue, Medicine, Journal of the National Comprehensive Cancer Network, National Comprehensive Cancer Network, Overalls, Face, Perelman Center for Advanced Medicine, Research, Pharmaceutical industry, Nursing, Medical imaging, Life, MD

PLYMOUTH MEETING, Pa., Oct. 12, 2023 /PRNewswire/ -- New research in the October 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that intensive local-regional treatment to remove as much tumor as possible (known as "debulking"), in addition to standard systemic therapy, does not impact overall quality of life significantly for people with metastatic colorectal cancer.

Key Points: 
  • Significant adverse events were reported in 21% of patients in the standard group and 43% of patients who also received tumor debulking.
  • However, there were no statistical or clinically relevant differences according to patient-reported outcomes for overall health-related quality of life or fatigue.
  • "This could mean that the negative impact of complications on quality of life is temporary and eventually balances out with a decrease in tumor-related symptoms after treatment.
  • "Given the considerable amount of complications from local treatment, we had expected to see a bigger impact on overall and persistent quality of life in the experimental group.

CHOP and Penn Researchers Receive $50 Million NIH Grant to Study Impact of Environmental Factors on Pregnancy and Children's Health

Retrieved on: 
Monday, October 2, 2023
Penn Center, Perelman School of Medicine at the University of Pennsylvania, Medicaid, Pregnancy, Obesity, Asthma, Diet, University, CHOP, Environmental toxicology, Culture, Sleep, ECHO, Health equity, Research, Doctor of Philosophy, Penn, Bangladesh Technical Education Board, MSCE, Patient, Child, Preterm birth, Biophysical environment, University of Pennsylvania Health System, Environmental Health (journal), Hospital, Health, MPH, Environment, NIH, Children's Hospital of Philadelphia, Birth control, Nursing, Epidemiology, MD

PHILADELPHIA, Oct. 2, 2023 /PRNewswire/ -- A multidisciplinary group of researchers from Children's Hospital of Philadelphia (CHOP) and Penn Medicine have received a $50 million grant from the National Institutes of Health (NIH) to study the impact of environmental influences on pregnancy and children's health. The research program is part of the NIH's Environmental influences on Child Health Outcomes (ECHO) Program, which funds research to uncover how environmental exposures during preconception, pregnancy and early life affect children's long-term health.

Key Points: 
  • PHILADELPHIA, Oct. 2, 2023 /PRNewswire/ -- A multidisciplinary group of researchers from Children's Hospital of Philadelphia (CHOP) and Penn Medicine have received a $50 million grant from the National Institutes of Health (NIH) to study the impact of environmental influences on pregnancy and children's health.
  • The research program is part of the NIH's Environmental influences on Child Health Outcomes (ECHO) Program , which funds research to uncover how environmental exposures during preconception, pregnancy and early life affect children's long-term health.
  • "We know that communities are not equally exposed to environmental toxicants, and we also know that health inequities and disparities are an ongoing public health problem.
  • "The Penn-CHOP ECHO Study Site now joins the Philadelphia Regional Center for Children's Environmental Health , the Penn Center of Excellence in Environmental Toxicology (CEET) , and the CHOP Center for Health Equity in leading the way to improve children's health, support environmental justice, and reduce health disparities."

MEMORA HEALTH PARTNERS WITH EISENHOWER HEALTH TO SUPPORT OVER 1,000 PATIENTS RECEIVING CANCER TREATMENT

Retrieved on: 
Tuesday, September 26, 2023
Partnership, Cancer, Triage, MBA, Emergency department, MD, Patient, Dwight D. Eisenhower, SAN, Nursing, University of Pennsylvania Health System, Financial toxicity, Hyperion (Gesaffelstein album), Health, Medical device

SAN FRANCISCO, Sept. 26, 2023 /PRNewswire/ -- Memora Health, the leading intelligent care enablement platform, today announced a partnership with Eisenhower Health, a comprehensive health care institution known for providing excellence in patient care. This partnership will support the launch of oncology care programs to support over 1,000 patients in receiving oral and infusion chemotherapy.

Key Points: 
  • SAN FRANCISCO, Sept. 26, 2023 /PRNewswire/ -- Memora Health, the leading intelligent care enablement platform, today announced a partnership with Eisenhower Health, a comprehensive health care institution known for providing excellence in patient care.
  • This partnership will support the launch of oncology care programs to support over 1,000 patients in receiving oral and infusion chemotherapy.
  • Through this partnership, Eisenhower will leverage Memora's platform to provide high-touch support and proactive symptom assessments to patients during their cancer treatments.
  • Together, Memora and Eisenhower are creating a more efficient way to extend clinical resources to deliver the same — or better — level of care to patients going through complex treatment, such as chemotherapy.

HHP and Hydra Health team up to expand amenities in hospitals and health systems nationwide

Retrieved on: 
Wednesday, September 13, 2023
Lactation, University of Pennsylvania Health System, Goldman Sachs, Operation, Restaurant, Cancer, Partnership, Hospital, Geisinger Health System, Harry Kloor, Patient, Geisinger, Pharmaceutical industry, HHP

HHP (Health Hospitality Partners) has acquired a majority stake in Hydra Health, allowing them to deepen their partnership and expand into new markets.

Key Points: 
  • HHP (Health Hospitality Partners) has acquired a majority stake in Hydra Health, allowing them to deepen their partnership and expand into new markets.
  • HHP and Hydra Health partnered to open the first Hydra Health studio at Geisinger's Henry Cancer Center in 2022.
  • Hydra Health co-founder and CEO Marie Kloor will now serve as Vice President, Operations & Development at HHP.
  • Kloor began her career in investment management at Goldman Sachs before launching Hydra Health.

Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency

Retrieved on: 
Wednesday, August 30, 2023
Emergent BioSolutions, Critical care, Emergency, Nasal spray, Life, Education, EBS, Naloxone, Policy, School, International Overdose Awareness Day, Patient, Love, OTC, University of Pennsylvania Health System, Family, Fentanyl, NYSE, Pharmaceutical industry, Emergent

Over-the-counter (OTC) access to NARCAN® Nasal Spray offers more people the ability to respond in an opioid emergency, helping to save lives and keep loved ones and communities safe.

Key Points: 
  • Over-the-counter (OTC) access to NARCAN® Nasal Spray offers more people the ability to respond in an opioid emergency, helping to save lives and keep loved ones and communities safe.
  • “Picking up NARCAN® Nasal Spray at the store is not a sign that your family has “a problem,” in fact it shows you are prepared just in case.
  • The Manufacturer’s Suggested Retail Price of NARCAN® Nasal Spray is $44.99 per carton, which is equivalent to roughly $22.50 per dose.
  • While Emergent works with partners to help maintain access and affordability, the price of the product is set by individual retailers.